Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan
Company Announcements

Aurinia’s Lupus Drug LUPKYNIS Wins Approval in Japan

Story Highlights

Aurinia Pharmaceuticals (AUPH) has released an update.

Aurinia Pharmaceuticals Inc. celebrates the Japanese approval of LUPKYNIS (voclosporin) to treat lupus nephritis, marking a significant milestone in collaboration with Otsuka Pharmaceutical. This approval, backed by the AURORA Clinical Program’s positive data, will address the high incidence of the disease in Japan. Additionally, Aurinia is set to receive a $10 million payment and royalties on net sales in Japan.

For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.

Related Articles
Radhika Saraogi3 Best Stocks to Buy Now, 11/11/2024, According to Top Analysts 
TipRanks Auto-Generated NewsdeskAurinia Pharmaceuticals Reports Strong Growth and Strategic Restructuring
TheFlyUnusually active option classes on open November 7th
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App